Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: First-in-humans study

Journal of Nuclear Medicine

Volumn 53, Issue 8, 2012, Pages 1207-1215

  Pfeifer, Andreas ^a,b,c   Knigge, Ulrich ^a,b,c   Mortensen, Jann ^a,c   Oturai, Peter ^a,c   Berthelsen, Anne Kiil ^a,c   Loft, Annika ^a,c   Binderup, Tina ^a,b,c   Rasmussen, Palle ^d   Elema, Dennis ^d   Klausen, Thomas Levin ^a,c   Holm, Søren ^a,c   Von Benzon, Eric ^a,c   Højgaard, Liselotte ^a,c   Kjaer, Andreas ^a,b,c  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ENETS Center of Excellence for Neuroendocrine Tumors   (Denmark)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

111In DTPA octreotide; 64Cu DOTA Tyr 3 octreotate; First in humans study; Neuroendocrine tumors; Positron emission tomography

Indexed keywords

IOVERSOL; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TETRAXETAN OCTREOTIDE[3 TYROSINE] CU 64; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; FIRST IN HUMAN STUDY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; IMAGE RECONSTRUCTION; MALE; NEUROENDOCRINE TUMOR; PHARMACOLOGICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIOACTIVITY; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZED UPTAKE VALUE; WHOLE BODY PET;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIATION DOSAGE; RADIOCHEMISTRY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84864757306     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.101469     Document Type: Article

References (28)

1. 111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM. 1998;91:295-301.
2. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
3. 18F-FDG PET. J Nucl Med. 2010;51:704-712.
4. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-846. (Pubitemid 32662546)
5. 123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
6. 177Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology. 2011;93:189-196.
7. 111In- pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441-1448.
8. Balon HR, Brown TL, Goldsmith SJ, et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol. 2011;39:317-324.
9. 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-2010.
10. 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51:875-882.
11. Schäfers KP. The promise of nuclear medicine technology: status and future perspective of high-resolution whole-body PET. Phys Med. 2008;24:57-62.
12. Townsend DW. Physical principles and technology of clinical PET imaging. Ann Acad Med Singapore. 2004;33:133-145. (Pubitemid 38684848)
13. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282. (Pubitemid 30167697)
14. Li WP, Lewis JS, Kim J, et al. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjug Chem. 2002;13:721-728. (Pubitemid 34801113)
15. Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C, Kjaer A. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology. 2008;87:223-232. (Pubitemid 351748756)
16. Thisgaard H, Jensen M, Elema DR. Medium to large scale radioisotope production for targeted radiotherapy using a small PET cyclotron. Appl Radiat Isot. 2011;69:1-7.
17. Sobin LH, Gospodarowicz MK, Wittekind C. UICC: TNM Classification of Malignant Tumours, Seventh ed.Oxford, U.K.:Wiley-Blackwell; 2009: 94-99.
18. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401. (Pubitemid 44451313)
19. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757-762. (Pubitemid 47497934)
20. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027. (Pubitemid 43733519)
21. International Commission on Radiological Protection. ICRP publication 60: recommendations of the International Commission on Radiological Protection. Ann ICRP. 1991;21:1-3.
22. Disselhorst JA, Brom M, Laverman P, et al. Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med. 2010;51:610-617.
23. Sánchez-Crespo A, Andreo P, Larsson SA. Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging. 2004;31:44-51. (Pubitemid 38133540)
24. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945. (Pubitemid 46909922)
25. 64Cu-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213-221.
26. 68Ga-DOTA-TATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864-1870.
27. Ginj M, Zhang H, Eisenwiener KP, et al. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin Cancer Res. 2008;14:2019-2027. (Pubitemid 351551111)
28. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50:936-941.